Kisunla approval offers new option to treat early Alzheimer’s in Europe
The European Commission has approved Eli Lilly‘s monthly infusion therapy Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease. The treatment targets sticky protein clumps, or amyloid plaques, in the brain and is specifically indicated for people in the early stages of the disease who meet specific…